Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies. Pfizer’s GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the research gaps as outlined in the specific RFP.
Projects that will be considered for Pfizer support will focus on research in the following area:
o Use of diagnostic tools/biomarkers alone or in their combination and/or combined with imaging techniques to improve the early diagnosis of invasive fungal infections
Grant Application due date: May 25, 2022
Geographic Scope: Africa, Middle East, Latin America, and Asia Pacific Countries (except China, Japan, South Korea, Australia, and New Zealand)
• The institution and principal investigator (PI) must be based in one of the eligible countries noted above. • Only organizations are eligible to receive grants, not individuals or medical practice groups. • The applicant (PI) must have a medical or postdoctoral degree (MD, PhD, or equivalent) or a degree in Pharmacy, Mycology, Microbiology or Radiology. • Applicant must be affiliated with a host institution
• Individual projects requesting up to USD $60,000.00 will be considered. The estimated total available budget related to this RFP is USD $300,000.00. • Research is expected to be completed and submitted for presentation/publication within 2 years of study start. Smaller, highquality innovative grant requests with anticipated results within 12-18 months will be considered.